Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

被引：2

作者：

Zhu, Viola Weijia

Bestvina, Christine M.

Lopes, Gilberto

Hamm, John Turner

Johnson, Melissa Lynne

Lammers, Philip Edward

Le, Xiuning

Marathe, Omkar

Raez, Luis E.

Rao, Suman

Sabari, Joshua K.

Scheff, Ronald J.

Tapan, Umit

Thompson, Jonathan Robert

Karachaliou, Niki

Ellers-Lenz, Barbara

Brutlach, Sabine

Smit, Egbert F.

Wu, Yi-Long

机构：

[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[4] Norton Canc Inst PARENT, Louisville, KY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Baptist Canc Ctr, Memphis, TN USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Innovat Clin Res Inst, Anaheim, CA USA

[9] Mem Healthcare Syst, Hollywood, FL USA

[10] Medstar Franklin Sq Clin Res Ctr, Baltimore, MD USA

[11] NYU Langone Clin Canc Ctr, New York, NY USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA

[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[15] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[16] Merck KGaA, Dept Biostat, Darmstadt, Germany

[17] Merck KGaA, Darmstadt, Germany

[18] Netherlands Canc Inst, Amsterdam, Netherlands

[19] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS9136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9136

引用

下载

页数：3

共 50 条

[41] Afatinib plus bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial
Kobayashi, Nobuaki
Hashimoto, Hisashi
Kamimaki, Chisato
Nagasawa, Ryo
Tanaka, Katsushi
Kubo, Sousuke
Katakura, Seigo
Chen, Hao
Hirama, Nobuyuki
Ushio, Ryota
Aoki, Ayako
Nakashima, Kentaro
Teranishi, Shuhei
Manabe, Saki
Watanabe, Hiroki
Horita, Nobuyuki
Watanabe, Keisuke
Hara, Yu
Yamamoto, Masaki
Kudo, Makoto
Piao, Hongmei
Kaneko, Takeshi
THORACIC CANCER, 2020, 11 (08) : 2125 - 2129
[42] Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
Minari, Roberta
Bordi, Paola
La Monica, Silvia
Squadrilli, Anna
Leonetti, Alessandro
Bottarelli, Lorena
Azzoni, Cinzia
Lagrasta, Costanza Anna Maria
Gnetti, Letizia
Campanini, Nicoletta
Petronini, Pier Giorgio
Alfieri, Roberta
Tiseo, Marcello
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : E89 - E91
[43] Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
Hata, Akito
Katakami, Nobuyuki
Takase, Naoto
Kibata, Kayoko
Yamanaka, Yuta
Tamiya, Motohiro
Mori, Masahide
Kijima, Takashi
Morita, Satoshi
Sakai, Kazuko
Nishio, Kazuto
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[44] MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
Cho, Byoung Chul
Felip, Enriqueta
Hayashi, Hidetoshi
Thomas, Michael
Lu, Shun
Besse, Benjamin
Sun, Tao
Martinez, Melissa
Sethi, Seema N.
Shreeve, S. Martin
Spira, Alexander, I
FUTURE ONCOLOGY, 2022, 18 (06) : 639 - 647
[45] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
Huang, M. J.
Yu, M.
Gong, Y. L.
Li, Y. Y.
Liu, Y. M.
Peng, F.
Yu, Y.
Xiu, W. G.
Wang, Y. S.
Zou, B. W.
Fan, H.
Zhong, L. Q.
Liu, T. Q.
Wang, X. F.
Xu, Y.
Zhou, L.
Lu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S146
[46] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
Wehler, T.
Wehler, B.
Atmaca-Dirik, H.
Schulz, C.
Grohe, C.
Topsch, J.
Ehrlich, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
[47] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
Han, J-Y.
Sequist, L. V.
Ahn, M-J.
Cho, B. C.
Yu, H.
Kim, S-W.
Yang, J. C-H.
Lee, J. S.
Su, W-C.
Kowalski, D.
Orlov, S.
Cantarini, M.
Verheijen, R. B.
Mellemgaard, A.
Frewer, P.
Ou, X.
Oxnard, G.
ANNALS OF ONCOLOGY, 2019, 30
[48] Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Wu, Yi-Long
Cheng, Ying
Zhou, Jianying
Lu, Shun
Zhang, Yiping
Zhao, Jun
Kim, Dong-Wan
Soo, Ross Andrew
Kim, Sang-We
Pan, Hongming
Chen, Yuh-Min
Chian, Chih-Feng
Liu, Xiaoqing
Tan, Daniel Shao Weng
Bruns, Rolf
Straub, Josef
Johne, Andreas
Scheele, Jurgen
Park, Keunchil
Yang, James Chih-Hsin
LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : 1132 - 1143
[49] First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations The UNICORN Phase 2 Nonrandomized Clinical Trial
Okuma, Yusuke
Kubota, Kaoru
Shimokawa, Mototsugu
Hashimoto, Kana
Kawashima, Yosuke
Sakamoto, Tomohiro
Wakui, Hiroshi
Murakami, Shuji
Okishio, Kyoichi
Hayashihara, Kenji
Ohe, Yuichiro
JAMA ONCOLOGY, 2024, 10 (01) : 43 - 51
[50] Tepotinib plus gefitinib in patients with c-Met-positive/EGFR-mutant NSCLC: Recommended phase II dose (RP2D), tolerability, and efficacy
Wu, Y-L.
Soo, R.
Kim, D-W.
Yang, J.
Stammberger, U.
Chen, W.
Locatelli, G.
Park, K.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →